A Phase 1 Safety and Tolerability Study of Personalized Live, Attenuated, Double-Deleted Listeria Monocytogenes (pLADD) Immunotherapy in Adults With Metastatic Colorectal Cancer

Trial Profile

A Phase 1 Safety and Tolerability Study of Personalized Live, Attenuated, Double-Deleted Listeria Monocytogenes (pLADD) Immunotherapy in Adults With Metastatic Colorectal Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Listeria monocytogenes expressing tumour antigens Aduro Biotech (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; First in man
  • Sponsors Aduro BioTech
  • Most Recent Events

    • 15 Jun 2017 Status changed from planning to recruiting.
    • 01 Mar 2017 According to an Aduro BioTech media release, this study is expected to start in the second half of 2017.
    • 23 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top